Immune cells in the belly for stomach cancer spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immune cell (called a CAR NK cell) given directly into the belly, along with standard surgery and chemotherapy, for stomach cancer that has spread to the belly lining. The goal is to see if this treatment is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to make your own medical decisions.
- You must have stomach (gastric) or gastroesophageal junction cancer that has spread to the lining of the belly (peritoneum).
- You must be able to do most daily activities (ECOG performance status 0 or 1).
- You must be willing to have surgery to place a small tube in the belly for treatment and to give blood and fluid samples.
- If you are a woman who could become pregnant, you must agree to use birth control during treatment and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
Hear when a new Gastric Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.